Bevacizumab + Triplet Treatment for Untreated With Chemotherapy Metastatic Colorectal Cancer

NCT02497157 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: Oxaliplatin (L-OHP)
DRUG: Irinotecan hydrochloride hydrate (CPT-11)
DRUG: Continuous intravenous infusion of fluorouracil (CIV 5-FU)
DRUG: Levofolinate calcium (l-LV)
DRUG: Bevacizumab (Bmab)

Sponsor

Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan

Collaborators

[object Object]
[object Object]